News

GE HealthCare Receives FDA Clearance for Portrait Mobile, A First-Of-Its-Kind, Wireless Monitoring Solution Aiding Early Detection of Patient Deterioration

GE HealthCare’s smart phone-sized Portrait Mobile frees the patient from the hospital bed while providing continuous monitoring of vital signs,…

1 year ago

Health Karma(R) Group Announces Partnership with OXIO Health, Inc. to offer access to Centralized Personal Health Record using Artificial Intelligence

FORT LAUDERDALE, FL / ACCESSWIRE / August 14, 2023 / MediXall Group Inc. (OTC PINK:MDXL) ("MediXall"), an innovative virtual health…

1 year ago

Curated Mental Health Expands Services to New Location in Williamsburg

BROOKLYN, NY / ACCESSWIRE / August 14, 2023 / Curated Mental Health proudly announces its expansion to a new location…

1 year ago

Bio-Conscious Announces Breakthrough in Forecasting Nocturnal Hypoglycemia Events Using Machine Learning (ML) Techniques and CGM data.

VANCOUVER, BC / ACCESSWIRE / August 14, 2023 / Bio Conscious Technologies Inc. ("Bio Conscious Technologies" or the "Company"), a…

1 year ago

Stemtech Announces China Market Expansion

Stemtech Unveils Bold Vision ‘Grand China Market Plan' to Supercharge China's Thriving Health and Wellness Landscape Amidst $ 683 Billion…

1 year ago

Biotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15th

REDWOOD CITY, CA / ACCESSWIRE / August 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS)…

1 year ago

Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses

Scientific Paper Presented at Research SymposiumJACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic…

1 year ago

Jaguar Health Reports Second Quarter 2023 Financial Results

Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3…

1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed…

1 year ago